iShares Biotechnology ETF
646 hedge funds and large institutions have $5.66B invested in iShares Biotechnology ETF in 2019 Q2 according to their latest regulatory filings, with 68 funds opening new positions, 182 increasing their positions, 247 reducing their positions, and 82 closing their positions.
New
Increased
Maintained
Reduced
Closed
more ownership
Funds ownership: →
more capital invested
Capital invested by funds: $ → $
less funds holding
Funds holding: →
less funds holding in top 10
Funds holding in top 10: →
17% less first-time investments, than exits
New positions opened: 68 | Existing positions closed: 82
26% less repeat investments, than reductions
Existing positions increased: 182 | Existing positions reduced: 247
35% less call options, than puts
Call options by funds: $560M | Put options by funds: $859M
Holders
646
Holding in Top 10
14
Calls
$560M
Puts
$859M
Top Buyers
| 1 | +$313M | |
| 2 | +$183M | |
| 3 | +$64.8M | |
| 4 |
TEE
Tibra Equities Europe
London,
United Kingdom
|
+$58.9M |
| 5 |
N
Natixis
Paris,
France
|
+$54.6M |
Top Sellers
| 1 | -$123M | |
| 2 | -$88.5M | |
| 3 | -$82.4M | |
| 4 |
Morgan Stanley
New York
|
-$66.2M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$55.2M |